Fig. 2: Subgroup analysis of patients who underwent remission and progression during follow-up. | Blood Cancer Journal

Fig. 2: Subgroup analysis of patients who underwent remission and progression during follow-up.

From: Ibrutinib plus fludarabine, cyclophosphamide and rituximab (iFCR) as initial treatment in chronic lymphocytic leukemia/ small lymphocytic leukemia with or without TP53 aberrations: a prospective real-world study in Chinese cohort

Fig. 2: Subgroup analysis of patients who underwent remission and progression during follow-up.

a Sankey diagram showing the dynamic change of BM-MRD levels and corresponding response assessment in patients who received three or four cycles of iFCR (n = 23) and in those who received six cycles of iFCR (n = 9); b Possible clonal evolution models of patients who progressed during treatment.

Back to article page